Blue Water Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Greenwich, Connecticut.
IPO Year: n/a
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
Business combination with Blue Water Acquisition Corp., a special purpose acquisition company, completed on September 9, 2021 Combined company to be renamed Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc.'s common stock and warrants will commence trading on the Nasdaq Global Market on September 10, 2021, under the ticker symbols "CRXT" and "CRXTW," respectively Gross proceeds totaled approximately $25.3 million NORTHBROOK, Ill. and GREENWICH, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc., a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women (
GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUW), a special purpose acquisition company ("Blue Water"), today announced that its stockholders have voted to approve the proposed business combination (the "Business Combination") with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women ("Clarus") at its special meeting of stockholders (the "Special Meeting") held today, August 27, 2021. Holders of approximately 73.95% of Blue Water's issued and outstanding shares cast votes at the Special Meeting. Approximately 69.57% o
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ: BLUW) ("Blue Water" or the "Company"), a special purpose acquisition company (SPAC) that previously announced a planned business combination with Clarus Therapeutics, Inc. ("Clarus"), announced today that the special meeting of its stockholders (the "Special Meeting") originally scheduled for Thursday, August 12, 2021, is being postponed to Friday, August 27, 2021. As a result of this change, the Special Meeting will now be held at 10:00 a.m., Eastern Time, on August 27, 2021, exclusively via a live audio webcast at https://www.cstproxy.com/bluewateracquisition/2021. Also as a result of this c
GREENWICH, Conn., July 30, 2021 /PRNewswire/ -- Blue Water Acquisition Corp. (NASDAQ:BLUW) ("Blue Water"), a special purpose acquisition company ("SPAC") led by Joseph Hernandez, today announced that it has scheduled a special meeting of its stockholders (the "Special Meeting") to, among other things, consider and vote on a proposal to approve the transactions contemplated by the previously announced merger agreement pursuant to which Clarus Therapeutics, Inc. ("Clarus") will merge with a wholly-owned subsidiary of Blue Water (the "Business Combination") and seek to become a publicly listed company. Subject to stockholder approval and satisfaction of customary closing conditions, Clarus and
NORTHBROOK, Ill. and NORTH ADELAIDE, South Australia, May 25, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and HavaH Therapeutics ("HavaH"), an Australia-based biopharmaceutical company developing androgen therapies for inflammatory breast disease and certain forms of breast cancer by using the innate breast-tissue-specific hormone/immune interface, today announced a licensing agreement whereby Clarus will acquire the exclusive worldwide (excluding Australia) development and commercialization rights for HAVAH T+Ai™ (CLAR-121).
NORTHBROOK, Ill. and GREENWICH, Conn., April 27, 2021 /PRNewswire/ -- Clarus Therapeutics Inc. ("Clarus"), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, and Blue Water Acquisition Corp. (NASDAQ:BLUW) ("Blue Water"), a special purpose acquisition company (SPAC), today announced a definitive business combination agreement that will result in Clarus becoming a publicly traded company. This transaction values Clarus at $379 million on a fully diluted basis, assuming no redemptions by Blue Water stockholders. In addition, current Clarus stakeholders will invest an additional $25 million in Clarus
New York, NY, April 22, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUWU) (the "Company") announced today that it received a notice ("Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2020 (the "Form 10-K") with the Securities and Exchange Commission ("SEC"). The Notice has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. As previously disclosed in the Current Report on Fo
4 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
4 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)
SC 13G/A - Blue Water Acquisition Corp. (0001817944) (Subject)
SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)
SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)
SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)
SC 13G - Blue Water Acquisition Corp. (0001817944) (Subject)
8-K - Blue Water Acquisition Corp. III (0002050501) (Filer)
424B4 - Blue Water Acquisition Corp. III (0002050501) (Filer)
CERT - Blue Water Acquisition Corp. III (0002050501) (Filer)
EFFECT - Blue Water Acquisition Corp. III (0002050501) (Filer)
S-1MEF - Blue Water Acquisition Corp. III (0002050501) (Filer)
8-A12B - Blue Water Acquisition Corp. III (0002050501) (Filer)
S-1/A - Blue Water Acquisition Corp. III (0002050501) (Filer)
S-1/A - Blue Water Acquisition Corp. III (0002050501) (Filer)
S-1/A - Blue Water Acquisition Corp. III (0002050501) (Filer)
S-4/A - Blue Water Acquisition Corp. (0001817944) (Filer)
GREENWICH, Conn., July 30, 2021 /PRNewswire/ -- Blue Water Acquisition Corp. (NASDAQ:BLUW) ("Blue Water"), a special purpose acquisition company ("SPAC") led by Joseph Hernandez, today announced that it has scheduled a special meeting of its stockholders (the "Special Meeting") to, among other things, consider and vote on a proposal to approve the transactions contemplated by the previously announced merger agreement pursuant to which Clarus Therapeutics, Inc. ("Clarus") will merge with a wholly-owned subsidiary of Blue Water (the "Business Combination") and seek to become a publicly listed company. Subject to stockholder approval and satisfaction of customary closing conditions, Clarus and
4 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
3 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
3/A - Blue Water Acquisition Corp. III (0002050501) (Issuer)
4 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
3 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
3 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
3 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
3 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
3 - Blue Water Acquisition Corp. III (0002050501) (Issuer)
3 - Blue Water Acquisition Corp. III (0002050501) (Issuer)